News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|April 4, 2025

Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration

Experts discuss how institutions can address the resource and bandwidth challenges that come with administering complex therapies like bispecifics.

Episodes in this series

EP. 1 Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

EP. 1 Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

3 experts are featured in this series.

EP. 2 Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals

3 experts are featured in this series.

EP. 3 How Bispecific Antibodies Are Reshaping Cancer Care

3 experts are featured in this series.

EP. 4 Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access

3 experts are featured in this series.

EP. 5 Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

3 experts are featured in this series.

EP. 6 Overcoming Key Operational Challenges in Integrating Bispecific Therapies

3 experts are featured in this series.

EP. 7 Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

3 experts are featured in this series.

EP. 8 Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies

3 experts are featured in this series.

EP. 9 Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy

3 experts are featured in this series.

EP. 10 Optimizing Bispecific Antibody Administration With EHR and Technology Solutions

3 experts are featured in this series.

EP. 11 Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration

3 experts are featured in this series.

EP. 12 Payer and Reimbursement Considerations for Bispecific Therapies

3 experts are featured in this series.

EP. 13 Emerging Therapeutic Areas for Bispecific Antibodies

3 experts are featured in this series.

EP. 14 Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities

3 experts are featured in this series.

EP. 15 Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Video content above is prompted by the following:

How can institutions address the resource and bandwidth challenges that come with administering complex therapies like bispecifics?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Alynlam | Image credit: Veronique - stock.adobe.com

Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM

ByPearl Steinzor

September 4th 2026

Andrew Kuykendall, MD | Image Credit: Moffitt Cancer Center

Rusfertide Approval Aims to Close PV Hematocrit Control Gaps

ByAndrew Kuykendall, MD,Maggie L. Shaw

September 4th 2026

gMG Rescue Therapy Access Varies by Hospital: Richard Nowak, MD, MS

ByHabiba Atta,Richard J. Nowak, MD, MS

September 4th 2026

Keith Bellovich, Do, MBA

CKM Guideline Aims to Break Down Specialty Silos: Keith Bellovich, DO

ByGiuliana Grossi,Keith Bellovich, DO, MBA

September 3rd 2026

Drs Jeff Romine and Kofi Essel

Grocery Assistance Shows Potential in Diabetes Care and Beyond

ByBrooke McCormick,Jeff Romine, PhD,Kofi Essel, MD, MPH

Published: September 3rd 2026 | Updated: September 3rd 2026

Trending on AJMC

Multiagonists Outpace Older GLP-1 Drugs for Weight Loss

Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM

FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations

The Next Frontier in Hepatitis B Functional and Virologic Cure

Cardiac Risks of COVID-19 Vaccine vs Infection: Eman Toraih, MD, PhD